ArticleIJID regions2024
A serosurvey examining exposure to
Article in IJID regions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Reassessing Regional Tick-Borne Encephalitis Endemicity in Poland Through Seroprevalence Analysis in Blood Donors, 2021-2022.Pathogens (Basel, Switzerland) · 2026Article
- Infection and Vaccination-Induced Tick-Borne Encephalitis Virus IgG Antibody Prevalence in the Austrian Federal State of Upper Austria, a High-Risk Region for TBEV.Epidemiologia (Basel, Switzerland) · 2026Article
- Prevalence and Risk Factors ofPathogens (Basel, Switzerland) · 2026Article
- Anti-NMDAR antibodies are not prevalent in Lyme neuroborreliosis: a retrospective cohort study.BMC neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Methods: A total of 1000 plasma samples equally distributed (n = 200) from all five Danish regions were analyzed. Commercially available enzyme-linked immunosorbent assays were used to screen the samples for immunoglobulin G antibodies against Bbsl and TBEV. The samples positive for antibodies against TBEV were further examined with a commercially available enzyme-linked immunosorbent assay and a Luminex-based TBEV suspension multiplex immunoassay for specific antibodies against non-structural protein 1 (NS1) antigen suggestive of previous infection. Results: A total of 62 samples tested positive for immunoglobulin G antibodies against Bbsl. A total of 40 samples were positive or borderline for antibodies against TBEV, indicating potential infection or vaccination. Of these, one had antibodies against NS1, indicating past infection. The seroprevalence of Bbsl was 6.2% (95% confidence interval 4.8-7.8), with equal seroprevalence in all five regions. The seroprevalence of TBEV was 0.1% (95% confidence interval 0.01-0.62%). Conclusions: The seroprevalence of Bbsl was similar throughout the country and corresponds well with previous studies. The seroprevalence of TBEV NS1 was low, which is in line with a low number of reported tick-borne encephalitis cases in Denmark. The NS1 positive sample was from the Capital Region, an endemic TBEV area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.